• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo

Question

Question: Is inhaled loxapine effective for acute treatment of agitation in schizophrenia?

Patients: 344 adults with DSM-IV schizophrenia who were in good general health and were agitated (Positive and Negative Syndrome Scale Excited Component (PANSS-EC) total score of ≥14 out of 35 and a score of ≥4 out of 7 on at least one of the five items). Participants were recruited from people admitted to hospital or a research unit, people already hospitalised for treatment of schizophrenia and individuals who were treated at a psychiatric emergency department.

Setting: 24 psychiatric research facilities, USA; February to June 2008.

Intervention: Inhaled loxapine 5 mg, inhaled loxapine 10 mg or inhaled placebo. Treatments were delivered by the Staccato system up to three times within a 24 h period. Dose 2 could be delivered if agitation had not subsided >2 h after dose 1, and dose 3 could be given ≥4…

Posted in: Journal Article Abstracts on 07/09/2011 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice